https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

21-Valent Pneumococcal Conjugate Vaccine Exhibits Consistent Safety and Immunogenicity Across Manufacturing Lots

21-Valent Pneumococcal Conjugate Vaccine Exhibits Consistent Safety and Immunogenicity Across Manufacturing Lots

Across 3 different manufacturing lots, V116 (21-valent pneumococcal conjugate vaccine) demonstrated consistent immunogenicity and efficacy against S pneumoniae, which causes pneumococcal diseases.

administrator

Related Articles